Orexo AB engages in the development of pharmaceuticals based on innovative drug delivery technologies. It operates through the following segments: US Pharma, Digital Therapeutics (DTx), and HQ and Pipelines. The US Pharma segment include sales of own pharmaceuticals in the US. The DTx segment comprises digital therapeutic venture. The HQ and Pipeline segment focuses in the out-licensed pharmaceuticals and costs for research and development, business development, global regulatory, and supply chain. The company was founded by Thomas Lundqvist on November 18, 1994 and is headquartered in Uppsala, Sweden.
Fundamental metrics to determine fair value of the stock
Company’s recent performance and margins
Dividend yield, history and sustainability
Financial position and solvency of the company